Accordingly, it has been recently shown that NRAS-mutated melanomas have lower PRDX2 (peroxiredoxin 2) expression compared to BRAF-mutated melanomas, which is correlated with lower survival and higher malignancy in patients. Here, PRDX2 is linked to melanoma.